TITLE

Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons' in Hamlet's dilemma?

AUTHOR(S)
Azad, Rajvardhan
PUB. DATE
November 2011
SOURCE
Indian Journal of Ophthalmology;Nov2011, Vol. 59 Issue 6, p421
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on the usage of intravitreal anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinopathy of prematurity (ROP). As per him, it is difficult for pediatric ophthalmologists and retinal surgeons to understand the utility of such drugs in ROP, particularly, in the area of systematic safety of the drugs. He opines that there should be proper investigation through scientific protocols and developmental outcomes before using the VEGF agents in ROP.
ACCESSION #
67520105

 

Related Articles

  • Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Darlow, Brian A.; Ells, Anna L.; Gilbert, Clare E.; Gole, Glen A.; Quinn, Graham E. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Mar2013, Vol. 98 Issue 2, pF170 

    The publication of the BEAT-ROP study of bevacizumab (Avastin) treatment for Zone I and II retinopathy of prematurity (ROP) has raised hopes that there might now be a simpler, cheaper and more effective treatment than laser therapy, the current standard of care. However, we would urge caution at...

  • An Evidence-Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 1. Retinopathy of Prematurity. Mititelu, Mihai; Chaudhary, Khurram M.; Lieberman, Ronni M. // Journal of Pediatric Ophthalmology & Strabismus;Nov2012, Vol. 49 Issue 6, p332 

    Recently there has been interest in the novel, off -label use of anti-vascular endothelial growth factor (anti-VEGF) agents for various stages of retinopathy of prematurity (ROP). The authors report on the quality and depth of new evidence published from 2009 to 2011 concerning the treatment of...

  • Mixed results seen with anti-VEGF therapy for children's retinal diseases. Trese, Michael T. // Ophthalmology Times;5/1/2007, Vol. 32 Issue 9, p60 

    The article highlights the result of an anti-vascular endothelial growth factor treatment of pediatric retinal diseases. Using pegaptanib sodium, this treatment was directed at familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP). It showed mixed results, with a...

  • Anti-vascular endothelial growth factor and retinopathy of prematurity. Sears, Jonathan E. // British Journal of Ophthalmology;Nov2008, Vol. 92 Issue 11, p1437 

    The article offers views on retinopathy of prematurity (ROP). According to the author, ROP may later on be a preventable disease. But he believes that the most rational method of prevention, meticulous oxygen supplementation, is difficult to implement because it demands a change in the mindset...

  • VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Pieh, C.; Agostini, H.; Buschbeck, C.; Krüger, M.; Schulte-Mönting, J.; Zirrgiebel, U.; Drevs, J.; Lagrèze, W. A. // British Journal of Ophthalmology;May2008, Vol. 92 Issue 5, p689 

    Aim: To study prospectively the plasma levels of vascular endothelial growth factor (VEGF-A), its soluble receptors sVEGFR-1, sVEGFR-2 and soluble Tie2 in premature infants. To identify their changes related to the onset of retinopathy of prematurity (ROP). Methods: Blood samples of 63 preterm...

  • Intravitreal Bevacizumab Following Laser Therapy for Severe Retinopathy of Prematurity. Erol, Nazmiye; Gürsoy, Hüseyin; Sahin, Afsun; Basmak, Hikmet // Journal of Pediatric Ophthalmology & Strabismus;Jul/Aug2010, Vol. 47 Issue 4, pe1 

    Trial of intravitreal bevacizumab injection in 7 eyes of 4 infants with continued retinopathy of prematurity progression despite previous laser therapy was reported. Six of the eyes benefited from the therapy. Intravitreal bevacizumab injection may be an alternative therapy in progressive stage...

  • Computer-aided quantification of retinal neovascularization. Stahl, A.; Connor, K.; Sapieha, P.; Willett, K.; Krah, N.; Dennison, R.; Chen, J.; Guerin, K.; Smith, L. // Angiogenesis;Sep2009, Vol. 12 Issue 3, p297 

    Rodent models of retinal angiogenesis play a pivotal role in angiogenesis research. These models are a window to developmental angiogenesis, to pathological retinopathy, and are also in vivo tools for anti-angiogenic drug screening in cancer and ophthalmic research. The mouse model of...

  • New treatments being evaluated for management of pediatric ophthalmic diseases. Biro, Ashley; Hasson, Matt; Mullin, David W. // Ocular Surgery News;1/10/2013, Vol. 31 Issue 1, p15 

    The article provides information on the evaluation of new treatments for management of pediatric ophthalmic diseases which include intravitreal lucentis for retinopathy of prematurity (ROP), occlusion for amblyopia, and variable doses of atropine for myopia.

  • Update on Anti-VEGF Monotherapy for ROP. Recchia, Franco M.; Capone Jr., Antonio // Review of Ophthalmology;Aug2011, Vol. 18 Issue 8, p56 

    The article offers updates in the use of anti-Vascular Endothelial Growth Factor (VEGF) treatment for retinopathy of prematurity (ROP). ROP is characterized by oxygen-induced attenuation of normal retinal vascularization following hypoxia-induced vasoproliferation. It provides an overview of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics